Rutten-van Mӧlken MPMH - Search Results

1

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.

Kanters TA, van der Ploeg AT, Kruijshaar ME, Rizopoulos D, Redekop WK, Rutten-van Mӧlken MPMH, Hakkaart-van Roijen L. Kanters TA, et al. Among authors: rutten van mlken mpmh. Orphanet J Rare Dis. 2017 Dec 13;12(1):179. doi: 10.1186/s13023-017-0731-0. Orphanet J Rare Dis. 2017. PMID: 29237491 Free PMC article.

2

Cost-effectiveness analysis of formoterol versus salmeterol in patients with asthma.

Rutten-van Mölken MP, van Doorslaer EK, Till MD. Rutten-van Mölken MP, et al. Pharmacoeconomics. 1998 Dec;14(6):671-84. doi: 10.2165/00019053-199814060-00007. Pharmacoeconomics. 1998. PMID: 10346418 Clinical Trial.

3

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Oostenbrink JB, Rutten-van Mölken MP, Monz BU, FitzGerald JM. Oostenbrink JB, et al. Value Health. 2005 Jan-Feb;8(1):32-46. doi: 10.1111/j.1524-4733.2005.03086.x. Value Health. 2005. PMID: 15841892 Free article.

4

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.

Rutten-van Mölken MP, Oostenbrink JB, Miravitlles M, Monz BU. Rutten-van Mölken MP, et al. Eur J Health Econ. 2007 Jun;8(2):123-35. doi: 10.1007/s10198-007-0039-4. Epub 2007 Mar 17. Eur J Health Econ. 2007. PMID: 17370096 Free PMC article. Clinical Trial.

5

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Rutten-van Mölken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM. Rutten-van Mölken MP, et al. Pharmacoeconomics. 2007;25(8):695-711. doi: 10.2165/00019053-200725080-00007. Pharmacoeconomics. 2007. PMID: 17640111 Clinical Trial.

6

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.

Hoogendoorn M, Welsing P, Rutten-van Mölken MP. Hoogendoorn M, et al. Curr Med Res Opin. 2008 Jan;24(1):51-61. doi: 10.1185/030079908x242917. Curr Med Res Opin. 2008. PMID: 18021492

7

Expected value of perfect information: an empirical example of reducing decision uncertainty by conducting additional research.

Oostenbrink JB, Al MJ, Oppe M, Rutten-van Mölken MP. Oostenbrink JB, et al. Value Health. 2008 Dec;11(7):1070-80. doi: 10.1111/j.1524-4733.2008.00389.x. Value Health. 2008. PMID: 19602213 Free article.

8

Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

Vemer P, Rutten-van Mölken MP. Vemer P, et al. Value Health. 2010 Mar-Apr;13(2):230-41. doi: 10.1111/j.1524-4733.2009.00612.x. Epub 2009 Sep 25. Value Health. 2010. PMID: 19804435 Free article.

9

Self-report versus care provider registration of healthcare utilization: impact on cost and cost-utility.

Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Mölken MP. Hoogendoorn M, et al. Int J Technol Assess Health Care. 2009 Oct;25(4):588-95. doi: 10.1017/S0266462309990432. Int J Technol Assess Health Care. 2009. PMID: 19845991

10

Largely ignored: the impact of the threshold value for a QALY on the importance of a transferability factor.

Vemer P, Rutten-van Mölken MP. Vemer P, et al. Eur J Health Econ. 2011 Oct;12(5):397-404. doi: 10.1007/s10198-010-0253-3. Epub 2010 May 30. Eur J Health Econ. 2011. PMID: 20512607 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters